Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with ...
Jaw-dropping patient videos and miraculous testimonials ignited a frenzy in China over a technique that aims to improve drainage from the brain. Now it is entering trials worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results